InflaRx reports topline results from Phase 2/3 COVID-19 trial


InflaRx (NASDAQ:IFRX) reported encouraging topline results from the first 30 COVID-19 patients treated with IFX-1 in a Phase 2/3 trial.  

IFX-1 is a monoclonal anti-human complement factor C5a antibody designed to control the inflammatory response. The trial evaluated IFX-1 treatment plus best supportive care, compared with best supportive care alone, for up to 28 days

The Phase 2 part of the trial was exploratory and not powered to show statistically significant differences in clinical endpoints. However, 28-day all-cause mortality in the IFX-1 treatment group was 13%, compared with 27% in the control group.

“InflaRx’s core expertise in the acute care field and our development work with IFX-1 in sepsis and viral lung injury put InflaRx in a scientifically strong position to develop IFX-1 in COVID-19,” Niels Riedemann, InflaRx’s CEO and co-founder, said in a statement.

“We are encouraged by these preliminary data,” he added.

The company is evaluating continuing the study with a Phase 3 portion, with 28-day all-cause mortality as the primary endpoint.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.